José Gerardo González‐González

Author

Universidad Autónoma de Nuevo León ORCID

Also Known As

Abdulrahman Al-Fares, Fernando Flores Lozano, Gonzalez-Gonzalez, Jose Gerardo, J G Gonzalez Gonzalez, J Gonzalez, J González, J. G. Gonzalez, J. G. Gonzalez-Gonzalez, J. G. González González, J. G. González-González

193

Publications

6.6K

Citations

H-Index

Concepts

All Affiliations

Universidad Autónoma de Nuevo León Hospital Universitario Dr José Eleuterio Gonzalez Mayo Clinic in Florida Mayo Clinic Mayo Clinic in Arizona

About

José Gerardo González‐González is an author at Universidad Autónoma de Nuevo León specializing in medicine, diabetes, and microbiology.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	16	19	3.6K
2	Health Sciences	5	5	141
3	Engineering	1	1	38
4	Public Health	1	1	286
5	Biochemistry	1	1	38

José Gerardo González‐González

Publications

4.9K

Citations

H-Index

Page 1

	Year	Citations
Albiglutide and cardiovascular outcomes in patients with type 2 diabetes and cardiovascular disease (Harmony Outcomes): a double-blind, randomised placebo-controlled trial Adrian F. Hernandez, Jennifer B. Green, Salim Janmohamed, The Lancet Diabetes ManagementCardiovascular DiseaseDiabetesClinical TrialsType 2	2018	1.7K
Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial Hiddo J.L. Heerspink, Hans‐Henrik Parving, Dennis L. Andress, The Lancet UrologyRenal DiseaseRenal EventsRenal FunctionDiabetes	2019	589
Once-weekly dulaglutide versus once-daily liraglutide in metformin-treated patients with type 2 diabetes (AWARD-6): a randomised, open-label, phase 3, non-inferiority trial Kathleen Dungan, Santiago Tofé, Thomas Först, The Lancet Diabetes ManagementOnce-weekly DulaglutideDiabetesType 2Clinical Trials	2014	477
Efficacy and Safety of Exenatide Once Weekly Versus Metformin, Pioglitazone, and Sitagliptin Used as Monotherapy in Drug-Naive Patients With Type 2 Diabetes (DURATION-4) David Russell‐Jones, Robert Cuddihy, M Hanefeld, Diabetes Care	2011	336
Efficacy and safety of dapagliflozin in patients with inadequately controlled type 1 diabetes (DEPICT-1): 24 week results from a multicentre, double-blind, phase 3, randomised controlled trial Paresh Dandona, Chantal Mathieu, Moshe Phillip, The Lancet Diabetes & Endocrinology Metabolic SyndromeType 1Diabetes ManagementHealth PolicyCardiovascular Disease	2017	286
Effects of dapagliflozin on mortality in patients with chronic kidney disease: a pre-specified analysis from the DAPA-CKD randomized controlled trial Hiddo J.L. Heerspink, C. David Sjöström, Niels Jongs, European Heart Journal	2021	118
Patients with osteoporosis prefer once weekly to once daily dosing with alendronate David L. Kendler, A W Kung, Ghada El‐Hajj Fuleihan, Maturitas Bone DiseaseBone HealthMedicineOsteoporosisOrthopaedic Surgery	2004	103
A pre-specified analysis of the Dapagliflozin and Prevention of Adverse Outcomes in Chronic Kidney Disease (DAPA-CKD) randomized controlled trial on the incidence of abrupt declines in kidney function Hiddo J.L. Heerspink, David Z.I. Cherney, Douwe Postmus, Kidney International	2021	92
Hyperglycemia related to high-dose glucocorticoid use in noncritically ill patients José Gerardo González‐González, Leonor Mireles-Zavala, René Rodríguez‐Gutiérrez, Diabetology & Metabolic Syndrome	2013	75
Acute toluene intoxication–clinical presentation, management and prognosis: a prospective observational study Carlos R. Cámara-Lemarroy, René Rodríguez‐Gutiérrez, Roberto Monreal‐Robles, BMC Emergency Medicine	2015	74

Page 1